drugset / Trial / NCT03556332
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Phase 2
Active not recruiting
41 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
Timeline
- Start
- 2018-07-02
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | — |
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | — |
| Background | Melphalan | Small molecule | 200 mg/m2 | — |